The advent of these new agents will likely necessitate a change in the diagnostic workflow—if the presence of HER2 overexpression provides an additional line of therapy, then routine HER2 testing (similar to checking for FGFR mutations or PD-L1 status) would be justified for all patients with advanced urothelial carcinoma. This evidence concerns the gene ERBB2 and urothelial carcinoma.